[Re-Analysis of Cancer Vaccine Patients with Immune-Related Clinical Response Criteria(irRC)].

Abstract

Anti-tumor responses induced by immunotherapy such as cancer vaccine are presumed to be mediated by induction of cancer-specific immune responses. Therefore, the immune-related response criteria(irRC)have been applied for cancer immunotherapies instead of the Response Evaluation Criteria in Solid Tumors(RECIST). Clinical responses of 91 patients enrolled in our cancer vaccine clinical studies were evaluated using RECIST. In this study, we re-analyzed their clinical responses using irRC. We identified 2 patients whose responses were evaluated as PD by RECIST, but as PR and SD by irRC, respectively. As these 2 patients showed relatively long survival rate, we concluded that irRC was suitable for the assessment of clinical outcomes in cancer immunotherapy.

• Authors: Kentaro Nishida, Takuro Saito, Shinya Urakawa, Masaki Mori, Kazuhiro Kakimi, Yuichiro Doki, Hisashi Wada
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 45 Issue 10 Pg. 1466-1468 (Oct 2018) ISSN: 0385-0684 [Print] Japan
• PMID: 30382047 (Publication Type: Journal Article)

Chemical References

• Cancer Vaccines

Topics

• Cancer Vaccines (therapeutic use)
• Humans
• Immunotherapy
• Neoplasms (immunology, therapy)
• Response Evaluation Criteria in Solid Tumors